Figure 5.

BMT of PTE-treated diabetic HSCs protects against diabetes-induced epigenetic changes on ERβ promoter and pro-inflammatory cytokine secretion in macrophages. Experimental rats were randomly separated into 4 groups as follows: rats with BMT of HSCs from CTL/VEH (BMT-CTL/VEH); rats with BMT of HSCs from STZ/VEH (BMT-STZ/VEH); rats with BMT of HSCs from STZ/RSV (BMT-STZ/RSV); and rats with BMT of HSCs from STZ/PTE (BMT-STZ/PTE). The rats were subjected to a model of cutaneous burn injury and the macrophages were collected for biomedical analysis after a 3-week period post-burn. (a) mRNA levels by qPCR, n = 4. (b) Protein quantitation by WB for (c), n = 5. (c) Representative picture for western blots. (d) ChIP analysis on ERβ promoter, n = 4. (e) mRNA levels for pro-inflammatory cytokines, n = 4. (f) IL1β secretion, n = 5. (g) IL6 secretion, n = 5. (h) MCP1 secretion, n = 5. For bars in graphs marked with an asterisk, p < 0.05 vs BMT-CTL/VEH group; for paragraph marks, p < 0.05 vs BMT-STZ/RSV group. Data are expressed as mean ± SEM. BMT bone marrow transplantation, PTE pterostilbene, HSCs hematopoietic stem cells, ERβ estrogen receptor β, CTL control, VEH vehicle, STZ streptozotocin, RSV resveratrol, IL1β interleukin-1β, IL6 interleukin-6, MCP1 monocyte chemoattractant protein-1, NRF1 nuclear respiratory factor-1, SOD2 superoxide dismutase 2, H3K9me2 histone H3 lysine 9 dimethylation, H3K9me3 histone H3 lysine 9 trimethylation, H3K27me2 H3 lysine 27 dimethylation, H3K27me3 H3 lysine 27 trimethylation, ChIP ChromatinImmunoprecipitation, WB western blotting, H&E Hematoxylin and eosin